Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$7.13 - $9.49 $29,946 - $39,858
4,200 New
4,200 $6,000
Q2 2023

Jul 18, 2023

BUY
$8.96 - $11.69 $6,272 - $8,183
700 Added 350.0%
900 $0
Q1 2023

May 01, 2023

BUY
$5.94 - $11.27 $1,188 - $2,254
200 New
200 $0
Q3 2022

Oct 25, 2022

BUY
$6.66 - $12.39 $1,998 - $3,717
300 New
300 $0
Q1 2022

Apr 14, 2022

SELL
$10.05 - $22.48 $400,995 - $896,952
-39,900 Reduced 82.61%
8,400 $23,000
Q4 2021

Jan 18, 2022

BUY
$17.78 - $33.08 $380,492 - $707,912
21,400 Added 79.55%
48,300 $42,000
Q3 2021

Oct 26, 2021

BUY
$10.93 - $23.55 $135,532 - $292,020
12,400 Added 85.52%
26,900 $13,000
Q2 2021

Jul 19, 2021

BUY
$10.0 - $14.52 $121,000 - $175,692
12,100 Added 504.17%
14,500 $16,000
Q1 2021

Apr 26, 2021

BUY
$12.3 - $18.73 $4,920 - $7,492
400 Added 20.0%
2,400 $10,000
Q3 2020

Oct 27, 2020

SELL
$13.19 - $16.66 $39,570 - $49,980
-3,000 Reduced 60.0%
2,000 $12,000
Q2 2020

Jul 22, 2020

BUY
$14.12 - $18.33 $24,004 - $31,160
1,700 Added 51.52%
5,000 $18,000
Q1 2020

May 07, 2020

BUY
$11.34 - $21.46 $3,402 - $6,438
300 Added 10.0%
3,300 $17,000
Q4 2019

Feb 06, 2020

SELL
$3.88 - $21.42 $13,580 - $74,970
-3,500 Reduced 53.85%
3,000 $10,000
Q3 2019

Oct 28, 2019

BUY
$5.34 - $6.59 $8,010 - $9,885
1,500 Added 30.0%
6,500 $22,000
Q2 2018

Aug 10, 2018

BUY
$5.06 - $6.36 $13,661 - $17,172
2,700 Added 117.39%
5,000 $2,000
Q4 2017

Jan 17, 2018

SELL
$4.53 - $7.09 $104,190 - $163,070
-23,000 Reduced 90.91%
2,300 $1,000
Q3 2017

Oct 17, 2017

BUY
$5.71 - $6.9 $144,463 - $174,570
25,300
25,300 $60,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.